Copyright © Inderes 2011 - present. All rights reserved.

Canatu

7.10 EUR

-1.93 %

2,357 following
Corporate customer

CANATU

First North Finland

Hardware Manufacturer

Technology

-1.93 %
-23.49 %
-13.20 %
-12.99 %
-16.47 %
-42.28 %
-27.25 %
-
-32.48 %

Canatu is a technology company active in deep technology that creates carbon nanotubes (Canatu CNT), related products and manufacturing equipment for the semiconductor, automotive and medical diagnostics industries. The company operates through two business models, firstly using their own reactors to develop and manufacture CNT products. Second, the company sells its CNT reactors and licenses its related technology, allowing customers to produce the products themselves under a limited license.

Read more
Market cap
246.9M EUR
Turnover
151.68K EUR
P/E (adj.) (26e)
-30.9
EV/EBIT (adj.) (26e)
-16.08
EV/S (26e)
8.18
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
8.50 EUR
Updated
26.03.2026
Disclaimer
Atte Riikola
Atte Riikola

Analyst

Latest research

Latest analysis report

Released: 27.03.2026

Latest extensive report

Released: 17.09.2024

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.4
2026

General meeting '26

25.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Canatu Capital Markets Day 2026
Webcast

Canatu Capital Markets Day 2026

Canatu invites analysts, investors, other capital market representatives, and media to its Capital Markets Day, taking place on Thursday, 26 March 2026.

Canatu

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
My scattered thoughts on today’s CMD (Capital Markets Day). I thought the analysts present did a great job challenging Canatu’s management, so big thumbs up for that. In 2024, Canatu reported the TAM (Total Addressable Market) for CNT pellicles to be approximately 3 billion euros...
3/26/2026, 7:32 PM
by Pandakarhu
28
Here’s the CMD comment: Inderes Canatu CMD: Kasvua vaille valmista - Inderes Vuodelle 2030 asetetut tavoitteet (lv. 100-150 MEUR ja EBIT 25-30 %) ovat mielestämme realistisesti saavutettavissa A lot of interesting things were heard and seen during the day. These will be further discussed...
3/27/2026, 6:43 AM
by Atte Riikola
19
It’s important to note here that we’re talking about relative growth rates, i.e., growth percentages. The relative shares of these businesses indicate that diagnostics will still be a very small business at the end of this decade, as has been in our own expectations. When you start...
3/26/2026, 7:07 AM
by Atte Riikola
16
I’ve been reading through the materials. It was, once again, confusing text, with real strategic thinking mixed in with flowery language. But that’s how it is with almost every company, so let’s not blame them too much for that. There wasn’t much new in the content itself, and the...
3/25/2026, 11:30 PM
by mardib
6
I would have hoped for answers to these questions: How confident is the management (e.g., best estimate of probability, %) that CNT will replace current technology? This may be self-evident to the management, but it should be communicated more explicitly to the market, as this is...
3/26/2026, 2:19 PM
by Kroisos Pennonen
4
CMD offered an interesting look into relevant markets for the coming years. CMD slides are available at Reports and presentations - Canatu On the medical side, Canatu will provide its own device for analyzing sensor results – could this be the first version of the device known in...
3/26/2026, 11:15 AM
by Koala
4
Those bullet-point questions were discussed to some extent in the Inderes video released this afternoon: Canatu CMD: Kohti skaalautuvaa arvonluontia - Inderes
3/26/2026, 2:23 PM
by Koala
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.